Patents by Inventor Thomas John Bleisch

Thomas John Bleisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES
    Publication number: 20230136885
    Abstract: The present invention provides a compound of Formula (I) wherein R is (II) or (III), or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 4, 2023
    Inventors: Thomas John BLEISCH, Douglas Linn GERNERT, Freddie Craig STEVENS
  • Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling
    Patent number: 11634423
    Abstract: The present invention provides a compound of Formula I: wherein R is or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: April 25, 2023
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Zhaogen Chen, Theodore Curtis Jessop
  • 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS
    Publication number: 20210253581
    Abstract: The present invention provides a compound of Formula I: wherein R is or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 19, 2021
    Inventors: Thomas John BLEISCH, Zhaogen CHEN, Theodore Curtis JESSOP
  • Dihydropyrido pyrimidine compounds as autotaxin inhibitors
    Patent number: 9550774
    Abstract: The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: January 24, 2017
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Robert Anthony Doti, Lance Allen Pfeifer, Bryan Hurst Norman
  • DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS
    Publication number: 20150368240
    Abstract: The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis.
    Type: Application
    Filed: April 4, 2014
    Publication date: December 24, 2015
    Applicant: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Robert Anthony Doti, Lance Allen Pfeifer, Bryan Hurst Norman
  • SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS
    Publication number: 20140275049
    Abstract: The present invention provides compounds of Formula I or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 18, 2014
    Inventors: Thomas John Bleisch, David Andrew Coates, Norman Earle Hughes, Scott Alan Jones, Bryan Hurst Norman
  • Excitatory amino acid receptor antagonists
    Patent number: 7601738
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: October 13, 2009
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Paul Leslie Ornstein
  • Indole Sulfonamide Modulators of Progesterone Receptors
    Publication number: 20090069400
    Abstract: Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.
    Type: Application
    Filed: January 17, 2007
    Publication date: March 12, 2009
    Inventors: Thomas John Bleisch, Christian Alexander Clarke, Jeffrey Alan Dodge, Scott Alan Jones, Jose Eduardo Lopez, Charles Willis Lugar, III, Brian Stephen Muehl, Timothy Ivo Richardson, Ying Kwong Yee, Kuo-Long Yu
  • Excitatory amino acid receptor antagonists
    Patent number: 7205313
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Excitatory amino acid receptor antagonists
    Patent number: 6924294
    Abstract: The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: August 2, 2005
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano
  • Excitatory amino acid receptor antagonists
    Patent number: 6855725
    Abstract: The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: February 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
  • Excitatory amino acid receptor antagonists
    Publication number: 20040138254
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Mark Alan Winter, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Amide, carbamate, and urea derivatives
    Publication number: 20040097499
    Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: July 3, 2003
    Publication date: May 20, 2004
    Inventors: MacKlin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamid H. Zarrinmayeh, Dennis Michael Zimmerman
  • Excitatory amino acid receptor antagonists
    Publication number: 20040063749
    Abstract: The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.
    Type: Application
    Filed: June 25, 2003
    Publication date: April 1, 2004
    Inventors: Thomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
  • Excitatory amino acid receptor antagonists
    Publication number: 20040053961
    Abstract: The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
    Type: Application
    Filed: June 12, 2003
    Publication date: March 18, 2004
    Inventors: Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez Manzanares, Ana Maria Escribano
  • Sulfonamide derivatives
    Publication number: 20030225163
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Application
    Filed: October 17, 2002
    Publication date: December 4, 2003
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, George William Cuff, Paul Leslie Ornstein, Dennis Michael Zimmerman
  • Amide, carbamate, and urea derivatives
    Patent number: 6617351
    Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulfonamide derivatives
    Patent number: 6500865
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: December 31, 2002
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
    Patent number: 6486175
    Abstract: The present invention relates to novel prodrug forms of 3S,4aR,6S,8aR-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid, to pharmaceutical compositions containing the prodrug forms, and to methods of using the prodrug forms.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: November 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Edward Louis Mattiuz, Paul Leslie Ornstein, Robert Eugene Stratford